Evidence map›Paper›PMID 25991668›Full record

ArticleOncotarget2015

Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage.

Hyeonseok Ko, Mi-Hyeon Jeong, Hyelin Jeon, Gi-Jun Sung, Youngsin So, InKi Kim, JaeKyoung Son, Sang-wook Lee, Ho-Geun Yoon, Kyung-Chul Choi

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Differential molecular mechanistic behavior of HDACs in cancer progression.Medical oncology (Northwood, London, England) · 2022
    Review
  9. Review
  10. Review
  11. Delphinidin and Its Glycosides' War on Cancer: Preclinical Perspectives.International journal of molecular sciences · 2021
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Hyeonseok KoLaboratory of Molecular Oncology, Cheil General Hospital & Women's Healthcare Center, College of Medicine, Dankook University, Seoul, South Korea.
Mi-Hyeon JeongDepartment of Biomedical Sciences and Department of Pharmacology, University of Ulsan College of Medicine, Seoul, Korea.
Hyelin JeonDepartment of Biomedical Sciences and Department of Pharmacology, University of Ulsan College of Medicine, Seoul, Korea.
Gi-Jun SungDepartment of Biomedical Sciences and Department of Pharmacology, University of Ulsan College of Medicine, Seoul, Korea.
Youngsin SoDepartment of Biomedical Sciences and Department of Pharmacology, University of Ulsan College of Medicine, Seoul, Korea.
InKi KimAsan Institute for Medical Research, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
JaeKyoung SonDepartment of Biomedical Sciences and Department of Pharmacology, University of Ulsan College of Medicine, Seoul, Korea.
Sang-wook LeeDepartment of Radiation Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Ho-Geun YoonDepartment of Biochemistry and Molecular Biology, Brain Korea PLUS Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea.
Kyung-Chul ChoiDepartment of Biomedical Sciences and Department of Pharmacology, University of Ulsan College of Medicine, Seoul, Korea.
Ulsan College · KRUniversity of Ulsan · KRAsan Medical Center · KRCheil General Hospital and Women's Healthcare Center · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TRAIL can induce apoptosis in some cancer cells and is an immune effector in the surveillance and elimination of developing tumors. Yes, some cancers are resistant to TRAIL. Delphinidin, a polyphenolic compound contained in brightly colored fruits and vegetables, has anti-inflammatory, anti-oxidant, and anti-tumorigenic activities. Here we showed that delphinidin sensitized TRAIL-resistant human prostate cancer cells to undergo apoptosis. Cells treated with delphinidin and TRAIL activated the extrinsic and intrinsic pathways of caspase activation. TRAIL-induced apoptosis in prostate cancer cells pretreated with delphinidin was dependent on death receptor 5 (DR5) and downstream cleavage of histone deacetylase 3 (HDAC3). In conclusion, delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis by inducing DR5, thus causing caspase-mediated HDAC3 cleavage. Our data reveal a potential way of chemoprevention of prostate cancer by enabling TRAIL-mediated apoptosis.

Indexed as

AnthocyaninsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCaspasesCell Line, TumorDrug SynergismHistone Deacetylase 3Histone DeacetylasesHumansMaleProstatic NeoplasmsReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing LigandTransfectionAnthocyaninsCaspasesdelphinidinHistone Deacetylase 3Histone DeacetylasesReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, humanapoptosisdelphinidinHDAC3prostate cancerTRAIL

Identifiers

PMID25991668
PMCPMC4496411
OpenAlexW2159859707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.